Hikma Sells Ben Venue Manufacturing Facilities to Xellia
Under the terms of the agreement, Xellia will acquire substantial parts of the Ben Venue site, including four sterile injectable manufacturing plants, which are not currently operational.
Hikma Pharmaceuticals has agreed to sell the former Ben Venue manufacturing facilities based in Bedford, Ohio, to Xellia Pharmaceuticals. Hikma acquired the Ben Venue assets from Boehringer Ingelheim in September 2014.
Under the terms of the agreement, Xellia will acquire substantial parts of the Ben Venue site, including four sterile injectable manufacturing plants, which are not currently operational.
Hikma will retain the Quality and Development Centre, an independent building with R&D laboratories, which played a key role in the tech transfer of the Bedford products to Hikma’s own manufacturing facilities. Since the acquisition of Ben Venue, Hikma has transferred a large number of modern, high-quality machines, such as lyophlizers and filling lines, to its manufacturing facilities in Portugal, Germany, and the US.
“We are very pleased to see that Xellia plans to restart commercial operations at the Ben Venue site, which will create jobs and further support the Bedford community,” commented Said Darwazah, chairman and CEO of Hikma, in a press statement. “We have successfully transferred equipment from Ben Venue to our different manufacturing sites, and will continue to benefit from the exceptional capabilities and skills of the Quality and Development Centre and the Bedford R&D teams on-site.”
Source: Hikma
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
